|Bid||0.00 x 1400|
|Ask||0.00 x 1000|
|Day's range||37.62 - 38.53|
|52-week range||26.07 - 46.10|
|Beta (5Y monthly)||0.37|
|PE ratio (TTM)||37.63|
|Forward dividend & yield||0.75 (1.95%)|
|Ex-dividend date||05 Apr 2021|
|1y target est||49.50|
SNN earnings call for the period ending December 31, 2020.
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce a new publication showing that its PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced the odds of surgical site infections (SSIs) by 63%*, the odds of seroma by 77%†, and the odds of dehiscence by 30%‡. A significant benefit of these reduced odds was an almost 2-day reduction in length of stay§, suggesting potential for substantial efficiency gains across the healthcare system1.